NTRA ▲ +0.4% - Natera, Inc. $NTRA - New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma Natera shares rose 0.4% following publication of new clinical validation data for its Signatera minimal residual disease test in lymphoma patients. The study provides clinical support for the blood-based assay's ability to detect cancer recurrence earlier, potentially strengthening the test's position in the growing MRD market. 01-SEP-2026 06:05 AM ET